SBIR/STTR Research Award
Infection Resistant Prostethic Valve Sewing Cuffs
Award amount
$99,994Program and phase
SBIR · Phase IAward year
2001Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- BIOMOD SURFACES
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
DESCRIPTION (Verbatim from the Applicant's Abstract): Cardiac valve replacement
using prosthetic valves is indicated when progression of degenerative disease
or bacterial infection of the native valve results in valvular dysfunction,
thereby impacting on cardiac output. Bacterial infection is a major
complication associated with implantation of these prosthetic valves.
Infections are localized to the prosthesis/tissue interface at the sewing cuff
leading to cuff and annular abscess formation. The goal of this phase I project
is to develop an infection-resistant knitted Dacron cuff material in vitro with
optimum antimicrobial properties via thermofixation (pad/heat) dyeing of the
antibiotic ciprofloxacin (Cipro). Our hypothesis is application of quinolone
antibiotics to Dacron biomaterials via dyeing technology can be optimized,
resulting in slow, sustained antibiotic release without the use of exogenous
binders. The specific aims of this proposal are to: optimize Cipro dyeing
conditions to knitted Dacron, characterize the physical properties of
Cipro-dyed Dacron, determine antibiotic release over time via
spectrophotometry, examine in vitro antimicrobial properties and assess
antibiotic release pharmacokinetics under simulated arterial flow conditions.
Phase II of this project will evaluate this novel technology in an in vivo
prosthetic valve model. This technology, if successful, will be become the
standard of care in the treatment of all forms of prosthetic endocarditis.
PROPOSED COMMERCIAL APPLICATION:
Current projections indicate that a greater number of cardiac prosthetic mechanical valves
will be implanted over the next ten years, with estimates in excess of 50,000 valves per
year. This technology, if applied to only mechanical heart valves, could have an annual
market in excess of $25-75 million. This technology can also be applied to vascular grafts,
carotid patch material, wound dressings and suture material. Additionally, this technology
may have commercial application in areas such as veterinary medicine, apparel or domestic
items.
Technology keywords
Not reported